Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oral hydration Clear all
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy

NCT01093131
View directory record Official record
Conditions
Contrast Induced Nephropathy
Interventions
Oral hydration, Oral sodium bicarbonate, Intravenous Hydration, Intravenous sodium bicarbonate
Other · Drug
Lead sponsor
The Western Pennsylvania Hospital
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Different Oral Rehydration Solutions on the Hydration Status of Healthy Males

NCT05428774
View directory record Official record
Conditions
Fluid Retention, Beverage Hydration Index, Hydration Status
Interventions
Test product 1, Test product 2, Placebo
Other
Lead sponsor
Liquid I.V.
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 24, 2023 · Synced Sep 2, 2026, 5:23 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Effect of Low Water Intake on Glucose Regulation Measured Using Continuous Glucose Monitoring

NCT06645431
View directory record Official record
Conditions
Blood Glucose Concentration, Blood Glucose Self Monitoring
Interventions
Water Intake
Behavioral
Lead sponsor
California Polytechnic State University-San Luis Obispo
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Luis Obispo, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 2, 2026, 5:23 AM EDT
Terminated Phase 1 Interventional

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT02277184
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT)
Drug · Radiation
Lead sponsor
Julie E. Bauman, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Results available

A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer

NCT00548548
View directory record Official record
Conditions
Adenocarcinoma
Interventions
Bevacizumab, Capecitabine, Cisplatin, Placebo, 5-fluorouracil
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
13
States / cities
Beverly Hills, California • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

NCT01399372
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Lymphoma, Neurotoxicity, Radiation Toxicity
Interventions
Rituximab, Cytarabine, Methotrexate, Procarbazine, Vincristine, low-dose whole-brain radiation therapy
Biological · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Sep 2, 2026, 5:23 AM EDT
Withdrawn Phase 2 Interventional

RCT of SPG Blocks for Post-dural Headache

NCT03560349
View directory record Official record
Conditions
Post-Dural Puncture Headache
Interventions
Lidocaine HCl Gel 2%, placebo gel
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 2, 2026, 5:23 AM EDT
Recruiting Phase 2 Interventional

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

NCT06023641
View directory record Official record
Conditions
Rhabdomyosarcoma
Interventions
Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Proton beam radiation or external beam radiation or brachytherapy, Liposomal irinotecan, Vinorelbine, Temozolomide, Filgrastim, peg-filgrastim
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 22 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
3
States / cities
Palo Alto, California • Memphis, Tennessee • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP

NCT00774202
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
Rituxan, Cyclophosphamide, Vincristine, Prednisone, Higher Dose of Rituximab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
12 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 2 Interventional

A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer

NCT01693718
View directory record Official record
Conditions
Head and Neck
Interventions
Hydroxyurea, 5- Fluorouracil, Cisplatin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
59 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2024 · Synced Sep 2, 2026, 5:23 AM EDT
Terminated Phase 2 Interventional Results available

Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers

NCT00832637
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cholangiocellular Carcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct, Bile Duct Cancer, Periampullary Adenocarcinoma, Gallbladder Cancer, Extrahepatic Bile Duct Cancer
Interventions
Cisplatin, Erlotinib, Gemcitabine
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
2
States / cities
San Francisco, California • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Hydration on Gut Health and Thinking

NCT05315531
View directory record Official record
Conditions
Dehydration, Cognitive Change, Gastrointestinal Microbiota
Interventions
Water Intake
Dietary Supplement
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
19 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Sep 2, 2026, 5:23 AM EDT
Withdrawn Phase 2 Interventional

Dipyridamole/Magnesium To Improve Sickle Cell Hydration

NCT00276146
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
oral dipyridamole, oral magnesium, or a combination of both
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years and older
Timeline
Started 2005
U.S. locations
3
States / cities
Detroit, Michigan • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 1Phase 2 Interventional

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

NCT02315326
View directory record Official record
Conditions
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Interventions
Ibrutinib, HD- Methotrexate (MTX), Rituximab + HD- Methotrexate (MTX), procarbazine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 2, 2026, 5:23 AM EDT
Terminated Not applicable Interventional

Short-Term Fasting: Impact on Toxicity

NCT00936364
View directory record Official record
Conditions
Fasting in Malignant Solid Tumors
Interventions
Short-term fasting, Modified fast, Fasting
Other
Lead sponsor
University of Southern California
Other
Eligibility
19 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2025 · Synced Sep 2, 2026, 5:23 AM EDT
Terminated Not applicable Interventional Results available

Hydrotherapy for the Reversal of Oligohydramnios

NCT01682928
View directory record Official record
Conditions
Oligohydramnios
Interventions
IV/Oral Hydration and Bedrest, Hydrotherapy
Drug · Other
Lead sponsor
Pediatrix
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of a Dietary Supplement on Parameters of Skin Aging in Men and Women

NCT06083402
View directory record Official record
Conditions
Skin Aging
Interventions
HyaCera™, Placebo
Dietary Supplement
Lead sponsor
Natals, Inc. dba Ritual
Industry
Eligibility
25 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Not applicable Interventional Results available

Trial of Acupuncture for Radiation-Induced Xerostomia in Head and Neck Cancer

NCT02589938
View directory record Official record
Conditions
Radiation-Induced Xerostomia, Head and Neck Cancer, Radiation Toxicity, Oral Complications of Chemotherapy and Head/Neck Radiation
Interventions
Standard Oral Hygiene, Standard Oral Hygiene + True Acupuncture, Standard Oral Hygiene + Sham Acupuncture
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
36
States / cities
Burbank, California • San Francisco, California • San Jose, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 4 Interventional

A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium)

NCT00002125
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Foscarnet sodium
Drug
Lead sponsor
Astra USA
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Beverly Hills, California • Los Angeles, California • Redwood City, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 5:23 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Stress and Anxiety Effects on Overactive Bladder

NCT05087810
View directory record Official record
Conditions
Overactive Bladder, Stress, Psychological, Anxiety
Interventions
Psychological stress induction, Accelerated oral hydration
Behavioral · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Sep 2, 2026, 5:23 AM EDT
Active, not recruiting Phase 1 Interventional

Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

NCT05053659
View directory record Official record
Conditions
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Interventions
Loncastuximab tesirine, Venetoclax
Drug
Lead sponsor
Paolo Caimi, MD
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Results available

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

NCT00025259
View directory record Official record
Conditions
Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma, Childhood Mixed Cellularity Classical Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Childhood Nodular Sclerosis Classical Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
Interventions
Bleomycin Sulfate, Cisplatin, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Involved-Field Radiation Therapy, Prednisone, Vincristine Sulfate Liposome
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
1,734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
153
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 127 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 2, 2026, 5:23 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Preoperative Oral Hydration in the Ambulatory Arthroplasty Population

NCT05520593
View directory record Official record
Conditions
Same-day Discharge, Length of Stay
Interventions
Complex Carbohydrate Drink
Dietary Supplement
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 75 Years
Enrollment
312 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 2, 2026, 5:23 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Siplizumab for Sickle Cell Disease Transplant

NCT06078696
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Siplizumab, Exchange Transfusion, Total Body Irradiation, Stem Cell Infusion, Cyclophosphamide 50mg, Mesna, Sirolimus Oral Tablet, Rituximab or Biosimilar
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 2, 2026, 5:23 AM EDT